The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Novo Nordisk's 2013 sales performance.
Novo Nordisk and the Broad Institute of MIT and Harvard have announced a new research alliance to address ‘critical unmet clinical needs’ in diabetes and cardiometabolic diseases. ... The Novo side of the collaboration is secured through the Novo
Evidence from clinical trials showed that Mounjaro resulted in significant reductions in blood sugar levels and body weight in comparison to Novo Nordisk’s semaglutide injection, insulin therapy or a placebo.
The deal gives Lilly access to Versanis' lead asset, bimagrumab, a monoclonal antibody currently being assessed in a mid-stage trial as both a monotherapy and in combination with Novo
Novo Nordisk has announced its acquisition of Embark Biotech in a deal worth over 470m, marking another expansion of the Danish drugmaker’s cardiometabolic disease pipeline. ... We are thrilled to pass on the baton for our lead metabolic programme to
Boehringer Ingelheim's Jardiance (empagliflozin) and Novo Nordisk's Novolog/Fiasp (insulin aspart).
No results were found
REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical education website. Support...